ITMI20011986A0 - Metodo e composizione per l'attivazione di cellule presentanti l'antigene - Google Patents

Metodo e composizione per l'attivazione di cellule presentanti l'antigene

Info

Publication number
ITMI20011986A0
ITMI20011986A0 IT2001MI001986A ITMI20011986A ITMI20011986A0 IT MI20011986 A0 ITMI20011986 A0 IT MI20011986A0 IT 2001MI001986 A IT2001MI001986 A IT 2001MI001986A IT MI20011986 A ITMI20011986 A IT MI20011986A IT MI20011986 A0 ITMI20011986 A0 IT MI20011986A0
Authority
IT
Italy
Prior art keywords
activation
composition
presenting cells
antigen presenting
antigen
Prior art date
Application number
IT2001MI001986A
Other languages
English (en)
Inventor
Marco Bianchi
Angelo Manfredi
Original Assignee
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond filed Critical San Raffaele Centro Fond
Priority to IT2001MI001986A priority Critical patent/ITMI20011986A1/it
Publication of ITMI20011986A0 publication Critical patent/ITMI20011986A0/it
Priority to PCT/IB2002/004080 priority patent/WO2003026691A2/en
Priority to DE60233147T priority patent/DE60233147D1/de
Priority to AU2002341266A priority patent/AU2002341266B2/en
Priority to US10/489,878 priority patent/US20040242481A1/en
Priority to AT02775057T priority patent/ATE437652T1/de
Priority to EP02775057A priority patent/EP1432441B1/en
Priority to JP2003530326A priority patent/JP2005508913A/ja
Priority to CA002461091A priority patent/CA2461091A1/en
Publication of ITMI20011986A1 publication Critical patent/ITMI20011986A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT2001MI001986A 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene ITMI20011986A1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT2001MI001986A ITMI20011986A1 (it) 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene
PCT/IB2002/004080 WO2003026691A2 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells
DE60233147T DE60233147D1 (de) 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen
AU2002341266A AU2002341266B2 (en) 2001-09-25 2002-09-25 Use of HMGB1 for the activation of dendritic cells
US10/489,878 US20040242481A1 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells
AT02775057T ATE437652T1 (de) 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen
EP02775057A EP1432441B1 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells
JP2003530326A JP2005508913A (ja) 2001-09-25 2002-09-25 樹状細胞の活性化のためのｈｍｇｂ１の使用
CA002461091A CA2461091A1 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001986A ITMI20011986A1 (it) 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene

Publications (2)

Publication Number Publication Date
ITMI20011986A0 true ITMI20011986A0 (it) 2001-09-25
ITMI20011986A1 ITMI20011986A1 (it) 2003-03-25

Family

ID=11448420

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001MI001986A ITMI20011986A1 (it) 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene

Country Status (9)

Country Link
US (1) US20040242481A1 (it)
EP (1) EP1432441B1 (it)
JP (1) JP2005508913A (it)
AT (1) ATE437652T1 (it)
AU (1) AU2002341266B2 (it)
CA (1) CA2461091A1 (it)
DE (1) DE60233147D1 (it)
IT (1) ITMI20011986A1 (it)
WO (1) WO2003026691A2 (it)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US8354106B2 (en) 2005-06-16 2013-01-15 The Feinstein Institute For Medical Research Antibodies against HMGB1 and fragments thereof
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
WO2008053892A1 (fr) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Produit pharmaceutique servant à favoriser la régénération fonctionnelle d'un tissu endommagé
TW200900077A (en) 2007-02-15 2009-01-01 Univ Kyushu Nat Univ Corp Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody
JP5225109B2 (ja) * 2007-02-15 2013-07-03 国立大学法人 熊本大学 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
US20100173277A1 (en) * 2007-02-15 2010-07-08 Fukuoka University Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody
EP3097926B1 (en) 2007-11-01 2019-10-02 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
AU2009240885A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
WO2009133943A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
CA2778759A1 (en) 2009-10-28 2011-05-05 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
JP6242050B2 (ja) 2010-01-21 2017-12-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫応答を増強するワクチンベクターおよび方法
JP6351972B2 (ja) 2010-03-29 2018-07-04 ユニバーシティー オブ サザン カリフォルニア バイオフィルムの除去のための組成物および方法
KR101881611B1 (ko) 2010-06-09 2018-07-25 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
US20120128701A1 (en) * 2010-09-09 2012-05-24 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
DK3358011T3 (da) 2011-04-26 2020-05-11 Univ Osaka Peptid til inducering af regenerering af væv og anvendelse deraf
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
ES2673861T3 (es) 2012-10-25 2018-06-26 Genomix Co., Ltd. Método novedoso para tratar el daño a la médula espinal utilizando el fragmento de hmgb1
JP6253589B2 (ja) 2012-10-25 2017-12-27 株式会社ジェノミックス Ｈｍｇｂ１断片を利用した新規心筋梗塞の治療法
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (en) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
EP3328429A4 (en) 2015-07-31 2019-03-20 The Research Institute at Nationwide Children's Hospital PEPTIDES AND ANTIBODIES FOR THE REMOVAL OF BIOFILMS
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
WO2018047917A1 (ja) * 2016-09-09 2018-03-15 国立大学法人 東京大学 Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
WO2018139562A1 (ja) 2017-01-27 2018-08-02 株式会社ジェノミックス 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis

Also Published As

Publication number Publication date
DE60233147D1 (de) 2009-09-10
AU2002341266B2 (en) 2007-11-15
ATE437652T1 (de) 2009-08-15
EP1432441B1 (en) 2009-07-29
CA2461091A1 (en) 2003-04-03
JP2005508913A (ja) 2005-04-07
ITMI20011986A1 (it) 2003-03-25
US20040242481A1 (en) 2004-12-02
EP1432441A2 (en) 2004-06-30
WO2003026691A2 (en) 2003-04-03
WO2003026691A3 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
ITMI20011986A0 (it) Metodo e composizione per l'attivazione di cellule presentanti l'antigene
ITRM20030376A1 (it) Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
HUP0600688A2 (en) Methods of administering anti-tnf alpha antibodies
IL157142A0 (en) Modified antibodies and methods of use
EP1551875A4 (en) TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
HUE064610T2 (hu) Új anti-IL 13 antitestek és alkalmazásaik
PT1438068E (pt) Anticorpos inibidores de gdf-8 e utilizações dos mesmos
IL149701A0 (en) Use of anti-ctla-4 antibodies
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
DE60230868D1 (de) Criptoblockierende antikörper und deren verwendung
DE60223761D1 (de) Polierzusammensetzung und Polierverfahren unter deren Verwendung
AU2002365228A1 (en) Antigen panels and methods of using the same
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
AU2002316162A1 (en) Method of increasing anti-neugc antibody levels in blood
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
GB0119497D0 (en) Expression of modified antibodies in avian cells
ITVI20040174A1 (it) Anticorpo e metodo per l'identificazione di cellule dendritiche
IT1315150B1 (it) Dispositivo e metodo per l'assemblaggio di telai smontabili di mobili
EP1501870A4 (en) RSV PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES
AU2002338423A1 (en) Mycobacterial sulfation pathway proteins and methods of use thereof
ITMI20020052A0 (it) Procedimento per l'idrolisi selettiva di nucleosidi poliesteri
ITBO20010160A0 (it) Dispositivo d'inserimento di guarnizioni in sedi odi elementi allungati
ITBO20030419A1 (it) Metodo per la costruzione e l'assemblaggio di articoli per bigiotteria ed oreficeria.
ITUD20020075A1 (it) Metodo per la fabbricazione di occhiali componibili e modulari ed occhiali cosi' ottenuti